Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
PYRIMIDINE COMPOUND
Document Type and Number:
WIPO Patent Application WO/2010/113834
Kind Code:
A1
Abstract:
Disclosed is a novel and excellent method for preventing and/or treating cannabinoid-2 receptor-related diseases, which is based on an agonist action on cannabinoid-2 receptors. Specifically disclosed is a heterocyclic derivative mainly having two substituents, for example, a pyrimidine-5-carboxylic acid amide derivative having a substituted amino group at the 2-position, which has a strong agonist action on cannabinoid-2 receptors. The derivative can be an agent for preventing and/or treating diseases related to cannabinoid-2 receptors, such as inflammatory diseases and pains.

More Like This:
WO/2020/116296FLUORINATED PYRIMIDINE COMPOUND AND PRODUCTION METHOD THEREFOR
JPH0733748PYRIMIDINE DERIVATIVE AND HERBICIDE
JPH05125056PYRIMIDINE DERIVATIVE COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL ELECTROOPTICAL ELEMENT
Inventors:
MATSUSHIMA YUJI (JP)
KUBOTA HIROKAZU (JP)
HAMAGUCHI HISAO (JP)
OKAMOTO YOSHINORI (JP)
HONDO TAKESHI (JP)
NISHIGAKI FUSAKO (JP)
Application Number:
PCT/JP2010/055506
Publication Date:
October 07, 2010
Filing Date:
March 29, 2010
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ASTELLAS PHARMA INC (JP)
MATSUSHIMA YUJI (JP)
KUBOTA HIROKAZU (JP)
HAMAGUCHI HISAO (JP)
OKAMOTO YOSHINORI (JP)
HONDO TAKESHI (JP)
NISHIGAKI FUSAKO (JP)
International Classes:
C07D239/34; A61K31/505; A61K31/506; A61K31/5377; A61K31/538; A61K31/541; A61K31/55; A61P1/02; A61P1/04; A61P1/08; A61P1/10; A61P1/12; A61P1/14; A61P1/16; A61P1/18; A61P3/04; A61P3/10; A61P5/14; A61P7/00; A61P7/02; A61P7/06; A61P9/00; A61P9/02; A61P9/04; A61P9/06; A61P9/08; A61P9/10; A61P9/12; A61P11/00; A61P11/02; A61P11/06; A61P11/14; A61P13/10; A61P13/12; A61P15/00; A61P15/08; A61P17/00; A61P17/02; A61P17/04; A61P17/06; A61P17/16; A61P19/02; A61P19/04; A61P19/06; A61P19/08; A61P19/10; A61P21/00; A61P21/02; A61P21/04; A61P25/00; A61P25/02; A61P25/04; A61P25/06; A61P25/08; A61P25/14; A61P25/16; A61P25/18; A61P25/20; A61P25/22; A61P25/24; A61P25/28; A61P25/30; A61P27/02; A61P27/06; A61P27/12; A61P29/00; A61P29/02; A61P31/04; A61P31/06; A61P31/12; A61P31/18; A61P33/00; A61P35/00; A61P35/02; A61P37/02; A61P37/06; A61P37/08; A61P43/00; C07D239/38; C07D239/42; C07D239/48; C07D401/04; C07D401/06; C07D401/12; C07D403/04; C07D403/12; C07D405/12; C07D405/14; C07D409/12; C07D413/06; C07D451/04; C07D453/02; C07D491/107; C07D493/08
Domestic Patent References:
WO2004029026A12004-04-08
WO2004009027A22004-01-29
WO2005075464A12005-08-18
WO2005080342A12005-09-01
WO1996025397A11996-08-22
WO2005121140A12005-12-22
WO2006043260A22006-04-27
WO2007017237A12007-02-15
WO2007017264A22007-02-15
WO2007088168A12007-08-09
WO2008027812A22008-03-06
WO2004018433A12004-03-04
WO2004018434A12004-03-04
WO2005075440A12005-08-18
WO2005080349A12005-09-01
WO2005080350A12005-09-01
WO1997009315A11997-03-13
WO2006050476A22006-05-11
WO1997009325A11997-03-13
WO1998038171A11998-09-03
WO2007118859A12007-10-25
Foreign References:
JP2006501228A2006-01-12
JP2007523207A2007-08-16
JP2006510597A2006-03-30
US5811428A1998-09-22
US5935966A1999-08-10
Other References:
NATURE, vol. 346, 1990, pages 561 - 564
NATURE, vol. 365, 1993, pages 61 - 65
SCIENCE, vol. 310, 2005, pages 329 - 332
EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 23, 2006, pages 1530 - 1538
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 102, 2005, pages 3093 - 3098
BRITISH JOURNAL OF PHARMACOLOGY, vol. 139, 2003, pages 775 - 786
SCIENCE, vol. 316, 2007, pages 1494 - 1497
NATURE, vol. 434, 2005, pages 782 - 786
EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 573, 2007, pages 206 - 213
BRITISH JOURNAL OF PHARMACOLOGY, vol. 153, 2008, pages 2S6 - 289
EXPERT OPINION OF THERAPEUTIC TARGETS, vol. 11, 2007, pages 403 - 409
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 103, 2006, pages 696 - 701
JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, 1998, pages 413 - 419
JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 6, 2004, pages 105 - 111
TETRAHEDRON LETTERS, vol. 3 8, 1997, pages 211 - 214
PROG. MED., vol. 5, 1985, pages 2157 - 2161
"Pharmaceutical Research and Development", 1990, HIROKAWA PUBLISHING COMPANY
DRUG DESIGN, vol. 7, pages 163 - 198
"Greene's Protective Groups in Organic Synthesis", 2006
"Organic Functional Group Preparations", vol. 1, 1991, ACADEMIC PRESS INC.
"Jikken Kagaku Koza", vol. 16, 2005, MARUZEN
"Jikken Kagaku Koza", vol. 14, 2005, MARUZEN
MOLECULAR PHARMACOLOGY, vol. 48, 1995, pages 443 - 450
See also references of EP 2415765A4
Attorney, Agent or Firm:
MORITA, Hiroshi et al. (JP)
Morita 拓 (JP)
Download PDF:
View/Download PDF      PDF Help



 
Previous Patent: FLUX COMPOSITION FOR LEAD-FREE SOLDER, AND LEAD-FREE SOLDER COMPOSITION

Next Patent: METHOD FOR PRODUCING IMIDIC ACID COMPOUND